
EOM Pharmaceuticals Holdings, Inc. – OTC:IMUC
EOM Pharmaceuticals Holdings stock price today
EOM Pharmaceuticals Holdings stock price yearly change
EOM Pharmaceuticals Holdings key metrics
Market Cap | 1.96M |
Enterprise value | N/A |
P/E | 0.01 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.30 |
PEG ratio | N/A |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEOM Pharmaceuticals Holdings stock price history
EOM Pharmaceuticals Holdings stock forecast
EOM Pharmaceuticals Holdings financial statements
Dec 2022 | 0 | -464.52K | |
---|---|---|---|
Mar 2023 | 0 | 0 | |
Jun 2023 | 0 | 0 | |
Sep 2023 | 0 | 0 |
Jun 2018 | 3829392 | 401.94K | 10.5% |
---|---|---|---|
Mar 2023 | 0 | 0 | |
Jun 2023 | 0 | 0 | |
Sep 2023 | 0 | 0 |
Dec 2022 | -687.93K | 0 | 750K |
---|---|---|---|
Mar 2023 | 0 | 0 | 0 |
Jun 2023 | 0 | 0 | 0 |
Sep 2023 | 0 | 0 | 0 |
EOM Pharmaceuticals Holdings alternative data
Aug 2023 | 3 |
---|---|
Sep 2023 | 3 |
Oct 2023 | 3 |
Nov 2023 | 3 |
Dec 2023 | 3 |
Jan 2024 | 3 |
Feb 2024 | 3 |
Mar 2024 | 3 |
Apr 2024 | 3 |
May 2024 | 3 |
Jun 2024 | 3 |
Jul 2024 | 3 |
EOM Pharmaceuticals Holdings other data
Period | Buy | Sel |
---|---|---|
Feb 2015 | 149600 | 0 |
Nov 2015 | 10000 | 0 |
Patent |
---|
Application Filling date: 22 Oct 2018 Issue date: 12 Sep 2019 |
-
What's the price of EOM Pharmaceuticals Holdings stock today?
One share of EOM Pharmaceuticals Holdings stock can currently be purchased for approximately $0.06.
-
When is EOM Pharmaceuticals Holdings's next earnings date?
Unfortunately, EOM Pharmaceuticals Holdings's (IMUC) next earnings date is currently unknown.
-
Does EOM Pharmaceuticals Holdings pay dividends?
No, EOM Pharmaceuticals Holdings does not pay dividends.
-
How much money does EOM Pharmaceuticals Holdings make?
EOM Pharmaceuticals Holdings has a market capitalization of 1.96M.
-
What is EOM Pharmaceuticals Holdings's stock symbol?
EOM Pharmaceuticals Holdings, Inc. is traded on the OTC under the ticker symbol "IMUC".
-
What is EOM Pharmaceuticals Holdings's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of EOM Pharmaceuticals Holdings?
Shares of EOM Pharmaceuticals Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does EOM Pharmaceuticals Holdings have?
As Jul 2024, EOM Pharmaceuticals Holdings employs 3 workers.
-
When EOM Pharmaceuticals Holdings went public?
EOM Pharmaceuticals Holdings, Inc. is publicly traded company for more then 18 years since IPO on 19 Sep 2006.
-
What is EOM Pharmaceuticals Holdings's official website?
The official website for EOM Pharmaceuticals Holdings is eompharma.com.
-
Where are EOM Pharmaceuticals Holdings's headquarters?
EOM Pharmaceuticals Holdings is headquartered at 30721 Russell Ranch Rd Ste 140, Westlake Village, CALIFORNIA.
-
How can i contact EOM Pharmaceuticals Holdings?
EOM Pharmaceuticals Holdings's mailing address is 30721 Russell Ranch Rd Ste 140, Westlake Village, CALIFORNIA and company can be reached via phone at +1 818 264 2300.
EOM Pharmaceuticals Holdings company profile:

EOM Pharmaceuticals Holdings, Inc.
eompharma.comOTC
3
Biotechnology
Healthcare
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
Westlake Village, CALIFORNIA 07645
CIK: 0000822411
ISIN: US4525362046
CUSIP: 452536204